SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-149236
Filing Date
2024-05-29
Accepted
2024-05-29 16:34:07
Documents
15
Period of Report
2024-05-29
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d842843d8k.htm   iXBRL 8-K 36741
2 EX-99.1 d842843dex991.htm EX-99.1 8467
6 GRAPHIC g842843g81i98.jpg GRAPHIC 7268
  Complete submission text file 0001193125-24-149236.txt   186403

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fusn-20240529.xsd EX-101.SCH 2854
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fusn-20240529_lab.xml EX-101.LAB 18690
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fusn-20240529_pre.xml EX-101.PRE 11695
18 EXTRACTED XBRL INSTANCE DOCUMENT d842843d8k_htm.xml XML 3800
Mailing Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6
Business Address 270 LONGWOOD ROAD SOUTH HAMILTON A6 L8P 0A6 289-799-0891
Fusion Pharmaceuticals Inc. (Filer) CIK: 0001805890 (see all company filings)

IRS No.: 000000000 | State of Incorp.: Z4 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39344 | Film No.: 24999022
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)